XNAS
SDGR
Market cap1.98bUSD
Oct 08, Last price
26.39USD
1D
-3.30%
1Q
60.04%
IPO
-17.32%
Name
Schrodinger Inc
Chart & performance
P/E
—
P/S
7.71
EPS
—
Div yield, %
—
Shrs. gr., 5y
4.12%
Rev. gr., 5y
18.81%
Revenues
256m
+23.29%
Net income
-103m
L-44.81%
CFO
14m
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Key people
Ramy Farid
President, Chief Executive Officer, Director · since 2017
Richie Jain
Executive Vice President, Chief Financial Officer, Treasurer · since 2025
Karen Akinsanya
President - R&D Therapeutics · since 2022
Robert Abel
Executive Vice President, Chief Scientific Officer, Platform · since 2024
Mannix Aklian
Executive Vice President, Chief Commercial Officer, Global Head of Software Sales & Marketing · since 2025
Kenneth Lorton
Executive Vice President, Chief Operating Officer - Software · since 2024
Yvonne Tran
Chief People Officer, Executive Vice President, Chief Legal Officer · since 2023
Margaret Dugan
Chief Medical Officer · since 2023
Richard Friesner
Director · since 1990
Independent Director · since 2020
Gary Ginsberg
Independent Director · since 2020
Rosana Kapeller-Libermann
Independent Director · since 2019
Michael Lynton
Independent Chairman of the Board · since 2018
Independent Director · since 2022
Gary Sender
Independent Director · since 2019
Independent Director · since 2019
Independent Director · since 2025
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||